• The FDA approved Agilent’s PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic for patients with esophageal or gastroesophageal junction carcinoma who may be eligible for Keytruda.
• The test is indicated for tumors with PD-L1 Combined Positive Score ≥ 1.
• Keytruda is indicated in combination with platinum- and fluoropyrimidine-based chemotherapy for locally advanced or metastatic disease not amenable to surgical resection or definitive chemoradiation.
• PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260326909115) on March 26, 2026, and is solely responsible for the information contained therein.